The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China

Jin-xiang Cheng, Bo-lin Liu, Xiang Zhang, Yong-qiang Zhang, Wei Lin, Rui Wang, Yong-qin Zhang, Hong-ying Zhang, Li Xie, Jun-li Huo, Jin-xiang Cheng, Bo-lin Liu, Xiang Zhang, Yong-qiang Zhang, Wei Lin, Rui Wang, Yong-qin Zhang, Hong-ying Zhang, Li Xie, Jun-li Huo

Abstract

Background: Health related quality of life (HRQOL) has increasingly emphasized on cancer patients. The psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30, version 3.0) in brain tumor patients wasn't proven, and there was no baseline HRQOL in brain tumor patients prior to surgery.

Methods: The questionnaire EORTC QLQ-C30 (version 3.0) was administered at three time points: T1, the first or the second day that patients were hospitalized after the brain tumor suspected or diagnosed by MRI or CT; T2, 1 to 2 days after T1, (T1 and T2 were both before surgery); T3, the day before discharge. Clinical variables included disease histologic types, cognitive function, and Karnofsky Performance Status.

Results: Cronbach's alpha coefficients for multi-item scales were greater than .70 and multitrait scaling analysis showed that most of the item-scale correlation coefficients met the standards of convergent and discriminant validity, except for the cognitive functioning scale. All scales and items exhibited construct validity. Score changes over peri-operation were observed in physical and role functioning scales. Compared with mixed cancer patients assessed after surgery but before adjuvant treatment, brain tumor patients assessed pre-surgery presented better function and fewer symptoms.

Conclusions: The standard Chinese version of the EORTC QLQ-C30 was overall a valid instrument to assess HRQOL in brain tumor patients in China. The baseline HRQOL in brain tumor patients pre-surgery was better than that in mixed cancer patients post-surgery. Future study should modify cognitive functioning scale and examine test-retest reliability and response validity.

Figures

Figure 1
Figure 1
Summary of ANOVA results of QLQ-C30 grouped by preoperative cognition (n = 297), by KPS (n = 266) and by brain tumor types (n = 304). ***. Correlation is significant at the .001 level (2-tailed). **. Correlation is significant at the .01 level (2-tailed). *. Correlation is significant at the .05 level (2-tailed). Abbreviations: AP appetite loss, CF cognitive functioning; Cho cholesteatoma; CO constipation; Cra craniopharyngioma; DI diarrhea; DY dyspnea; Abnormal abnormal cognition; EF emotional functioning; FA fatigue; FI financial difficulties; KPS70 KPS ≤ 70; KPS80 KPS ≥ 80; NV nausea/vomiting; Normal normal cognition; PA pain; Pit pituitary adenoma; QL global health status/quality of life; SF social functioning; SL insomnia

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005;55(2):74–108. doi: 10.3322/canjclin.55.2.74.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. et al.The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365.
    1. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996;5(1):139–150. doi: 10.1007/BF00435979.
    1. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995;75(5):1151–1161. doi: 10.1002/1097-0142(19950301)75:5<1151::AID-CNCR2820750515>;2-Q.
    1. Zhao H, Kanda K. Testing psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) J Epidemiol. 2004;14(6):193–203. doi: 10.2188/jea.14.193.
    1. Cheng JX, Zhang X, Liu BL. Health-related quality of life in patients with high-grade glioma. Neuro-oncology. 2009;11(1):41–50.
    1. Bosma I, Reijneveld JC, Douw L, Vos MJ, Postma TJ, Aaronson NK, Muller M, Vandertop WP, Slotman BJ, Taphoorn MJ. et al.Health-related quality of life of long-term high-grade glioma survivors. Neuro-oncology. 2009;11(1):51–58.
    1. Liu R, Solheim K, Polley MY, Lamborn KR, Page M, Fedoroff A, Rabbitt J, Butowski N, Prados M, Chang SM. Quality of life in low-grade glioma patients receiving temozolomide. Neuro-oncology. 2009;11(1):59–68.
    1. Osoba D, Brada M, Prados MD, Yung WK. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro-oncology. 2000;2(4):221–228.
    1. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. Journal of neuro-oncology. 1997;34(3):263–278. doi: 10.1023/A:1005790632126.
    1. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. et al.The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–579.
    1. Yu ES, Liu WT, Levy P, Zhang MY, Katzman R, Lung CT, Wong SC, Wang ZY, Qu GY. Cognitive impairment among elderly adults in Shanghai, China. J Gerontol. 1989;44(3):S97–106.
    1. Karnofsky DA, Abelman WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;1:634–656. doi: 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>;2-L.
    1. Katzman R, Zhang MY, Ouang Ya Q, Wang ZY, Liu WT, Yu E, Wong SC, Salmon DP, Grant I. A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol. 1988;41(10):971–978. doi: 10.1016/0895-4356(88)90034-0.
    1. Fayers PM, Aaronson, Groenvold M, Curran D, A B. the EORTC Quality of Life Group. European Organisation for Research and Treatment of Cancer, Brussels; 2001. The EORTC QLQ-C30 Scoring Manual (3rd Edition)
    1. Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res. 2000;9(2):129–137. doi: 10.1023/A:1008981520920.
    1. Scott Neil W, Fayers Peter M, Aaronson Neil K, Andrew Bottomley, de Graeff Alexander, Mogens Groenvold, Chad Gundy, Michael Koller, Petersen Morten A, Sprangers MA. the EORTC Quality of Life Department. European Organisation for Research and Treatment of Cancer, Brussels; 2001. EORTC QLQ-C30 Reference Values.
    1. Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY. et al.Radiotherapy for glioblastoma in the elderly. The New England journal of medicine. 2007;356(15):1527–1535. doi: 10.1056/NEJMoa065901.
    1. Levin VA, Phuphanich S, Yung WK, Forsyth PA, Maestro RD, Perry JR, Fuller GN, Baillet M. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. Journal of neuro-oncology. 2006;78(3):295–302. doi: 10.1007/s11060-005-9098-5.
    1. Henriksson R, Malmstrom A, Bergstrom P, Bergh G, Trojanowski T, Andreasson L, Blomquist E, Jonsborg S, Edekling T, Salander P. et al.High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. Journal of neuro-oncology. 2006;78(3):321–326. doi: 10.1007/s11060-005-9106-9.
    1. Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E. et al.Health-related quality of life in patients with glioblastoma: a randomised controlled trial. The lancet oncology. 2005;6(12):937–944. doi: 10.1016/S1470-2045(05)70432-0.
    1. Taphoorn MJ, van den Bent MJ, Mauer ME, Coens C, Delattre JY, Brandes AA, Sillevis Smitt PA, Bernsen HJ, Frenay M, Tijssen CC. et al.Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol. 2007;25(36):5723–5730. doi: 10.1200/JCO.2007.12.7514.
    1. Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol. 2000;18(7):1481–1491.
    1. Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer. 2000;36(14):1788–1795. doi: 10.1016/S0959-8049(00)00165-9.
    1. Hauck EF, Barnett SL, White JA, Samson D. The presigmoid approach to anterolateral pontine cavernomas. Journal of Neurosurgery. 2010;113(4):701–708. doi: 10.3171/2010.1.JNS08413.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera